TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Hematology & Oncology
Division of General Internal Medicine
Division of Thoracic Medicine
更新時間：2024-03-21
楊志新Yang, James Chih-Hsin
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
63Publications
41
Zhang Y, Wang LF, Gao JH, Li L, Jiang P, Lv X, Yu LX, Yang J, Li RT, Liu BR. Clinical significance of epithelial-mesenchymal transition-related molecules in lung adenocarcinoma. Curr Oncol. 2019 Apr;26(2):e121-e127. doi: 10.3747/co.26.4471. Epub 2019 Apr 1. PMID: 31043817; PMCID: PMC6476438.
42
Liao BC, Griesing S, Yang JC. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890286. doi: 10.1177/1758835919890286. PMID: 31803256; PMCID: PMC6878608.
43
Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis CR, Millward M, Lord S, Gralla RJ, Yang JC, Mok T, Lee CK. Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncol. 2019 Jul;15(20):2371-2383. doi: 10.2217/fon-2019-0105. Epub 2019 Jun 25. PMID: 31354046.
44
Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, Park K, Soo RA, Chang JWC, Alip A, Peters S, Douillard JY. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019 Feb 1;30(2):171-210. doi: 10.1093/annonc/mdy554. PMID: 30596843.
45
Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang JC, Yu CJ. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019 Aug;117:107-115. doi: 10.1016/j.ejca.2019.05.032. Epub 2019 Jul 3. PMID: 31279301.
46
Hong ST, Lin H, Wang CS, Chang CH, Lin AM, Yang JC, Lo YL. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. J Nanobiotechnology. 2019 Aug 19;17(1):89. doi: 10.1186/s12951-019-0519-6. PMID: 31426807; PMCID: PMC6699136.
47
Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC. Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. Target Oncol. 2019 Feb;14(1):57-65. doi: 10.1007/s11523-019-00620-0. PMID: 30725402; PMCID: PMC6407737.
48
Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer (Auckl). 2019 Nov 13;10:125-130. doi: 10.2147/LCTT.S209231. PMID: 32009824; PMCID: PMC6859466.
49
Wu TH, Hsiue EH, Yang JC. Opportunities of circulating tumor DNA in lung cancer. Cancer Treat Rev. 2019 Aug;78:31-41. doi: 10.1016/j.ctrv.2019.07.002. Epub 2019 Jul 15. PMID: 31326635.
50
Hsiue EH, Lee PL, Chen YH, Wu TH, Cheng CF, Cheng KM, Yang PC, Chen HW, Lin PY, Chiang DL, Wu HD, Yang JC, Yu CJ. Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. J Formos Med Assoc. 2019 Jun;118(6):995-1004. doi: 10.1016/j.jfma.2019.02.007. Epub 2019 Mar 8. PMID: 30857753.
